Document:

EX-10.1

 Exhibit 10.1 

EXECUTION VERSION 
 CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

Clinical Trial Collaboration and Supply Agreement 

by and among 
 MSD
International GmbH, 
 MSD International Business GmbH, 

and 
 Collaborator (as
defined below) 
 Clinical Trial Collaboration and Supply Agreement - Information Sheet 

 

			
	MSD Agreement Number (LKR Number)	  	[***]
		
	Collaborator Entity Name	  	IO Biotech ApS
		
	Collaborator Address	  	[***]
		
	Collaborator Class Compound	  	[***]
		
	Collaborator Compound	  	IO102 + IO103
		
	Collaborator Clinical Trial	  	A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with Pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head and Neck (SCCHN), or Metastatic Urothelial Bladder Cancer (mUBC)
		
	Collaborator JDC Escalation Person Title	  	Chief Executive Officer
		
	Collaborator Notice Block	  	 IO Biotech ApS

[***]

		
	Effective Date	  	November 30, 2021 
		
	Safety Gate (Yes/No)	  	No

 CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT 

This Clinical Trial Collaboration and Supply Agreement is entered into as of the Effective Date, by and among MSD International GmbH
(“MSDIG”), MSD International Business GmbH (“MSDIB” and, collectively with MSDIG, “MSD”), each having a place of business at [***], and Collaborator (as defined below), having a place of business at
the Collaborator Address (as defined below). MSD and Collaborator are each referred to herein individually as a “Party” and collectively as the “Parties”. 

RECITALS 
  

	A.	 MSD holds intellectual property rights to the MSD Compound (as defined below) and is developing the MSD
Compound for the treatment of certain tumor types. 

  

	B.	 Collaborator is developing the Collaborator Compound (as defined below) for the treatment of certain tumor
types. 

  

	C.	 Collaborator desires to sponsor the Collaborator Clinical Trial (as defined below) in which the Collaborator
Compound and the MSD Compound would be dosed in Combination (as defined below). 

  

	D.	 MSD and Collaborator, consistent with the terms of this Agreement, desire to collaborate as described herein,
including by providing the MSD Compound and the Collaborator Compound for the MSD Compound Study (as defined below). 

NOW, THEREFORE, in consideration of the following mutual promises, covenants and conditions, the Parties, intending to be legally bound, agree
as follows: 
 1.    DEFINITIONS. 

For all purposes of this Agreement, the capitalized terms defined in this Article 1 and throughout this Agreement shall have the
meanings herein specified. 
  

	1.1.	 “Affiliate” means, with respect to either Party, a firm, corporation or other entity that, now
or hereafter, directly or indirectly owns or controls said Party, or, now or hereafter, is owned or controlled by said Party, or is under common ownership or control with said Party for so long as such control exists. The word
“control” as used in this definition means: (i) the direct or indirect ownership of fifty percent (50%) or more of the outstanding voting securities of a legal entity; or (ii) possession, directly or indirectly, of the
power to direct the management or policies of a legal entity through the ownership of voting securities, contract rights, voting rights, corporate governance or otherwise. 

 

	1.2.	 “Agreement” means this agreement. 

  
 2 

	1.3.	 “Alliance Manager” means the alliance managers appointed by the Parties in accordance with
Section 2.3 (Joint Development Committee; Managers). 

  

	1.4.	 “Applicable Law” means all federal, state, local, national and regional statutes, laws, rules,
regulations and directives applicable to a particular activity hereunder, including performance of clinical trials, medical treatment and the processing and protection of personal and medical data, that may be in effect from time to time, including:
(i) those promulgated by any Regulatory Authority; (ii) cGMP and GCP; (iii) Data Protection Law; (iv) export control and economic sanctions regulations that prohibit the shipment of United States-origin products and technology to
certain restricted countries, entities and individuals; (v) anti-bribery and anti-corruption laws pertaining to interactions with government agents, officials and representatives; (vi) laws and regulations governing payments to healthcare
providers; (vii) the listing or other rules or regulations of any securities regulator or stock exchange; and (viii) health, safety and environmental protections. 

 

	1.5.	 “Business Day” means any day other than a Saturday, Sunday, or a day on which commercial banks
located in the country (or, if in the United States, in the state) where the applicable obligations are to be performed are authorized or required by law to be closed. 

 

	1.6.	 “cGMP” means the Good Manufacturing Practices officially published and interpreted by EMA, FDA
and other applicable Regulatory Authorities as applicable to the Manufacture of the Compounds. 

  

	1.7.	 “Change of Control” means, with respect to the Collaborator, and except for any change
resulting solely from the change in the legal domicile of the Collaborator and/or its Affiliates (e.g., from ApS to US C-Corp entity): (a) the sale of all or substantially all of such Collaborator’s
assets or business relating to the Collaborator Compound; or (b) a merger, reorganization or consolidation involving Collaborator in which the voting securities immediately prior thereto cease to represent at least fifty percent (50%) of the
combined voting power of the surviving entity immediately after such merger, reorganization or consolidation; or (c) any Third Party (or group of Third Parties acting in concert) becoming the beneficial owner directly or indirectly, of fifty
percent (50%) or more of the total voting power of Collaborator. 

  

	1.8.	 “Clinical Quality Agreement” means an agreement to be entered into by the Parties pursuant to
Section 2.4 (Clinical Quality Agreement) to address and govern the quality and handling of clinical drug to be supplied by the Parties for use in the MSD Compound Study. 

 

	1.9.	 “Clinical Data” means Collaborator Clinical Data, Joint Clinical Data and MSD Clinical Data.

  
 3 

	1.10.	 “Clinical Safety Data” means all safety and tolerability data [***]. 

 

	1.11.	 “CMC” means “Chemistry Manufacturing and Controls” as such term of art is
used in the pharmaceutical industry. 

  

	1.12.	 “Collaborator” means the entity specified in the “Collaborator Entity Name” row of
the Information Sheet. 

  

	1.13.	 “Collaborator Address” means the address set forth for Collaborator in the “Collaborator
Address” row of the Information Sheet. 

  

	1.14.	 “Collaborator Background Patents” means any Patent Controlled by Collaborator or its
Affiliate that claims or covers the Combination and is not a Joint Patent. 

  

	1.15.	 “Collaborator Class Compound” means the class of compounds set forth
in the “Collaborator Class Compound” row of the Information Sheet. 

  

	1.16.	 “Collaborator Clinical Data” means all data (including raw data) and results generated by or
on behalf of either Party or at either Party’s direction, or by or on behalf of the Parties together or at their direction, [***] included in the Collaborator Clinical Trial. Collaborator Clinical Data does not include [***].

  

	1.17.	 “Collaborator Clinical Trial” means the clinical trial set forth in the
“Collaborator Clinical Trial” row of the Information Sheet. 

  

	1.18.	 “Collaborator Compound” means the compound set forth in the “Collaborator Compound”
row of the Information Sheet, [***]. 

  

	1.19.	 “Collaborator Compound Arm(s)” means any portion of the Collaborator Clinical Trial where
patients are intended to receive the Collaborator Compound either alone or in concomitant or sequential administration with one or more treatments, but not in combination with the MSD Compound. 

 

	1.20.	 “Collaborator Escalation Contact” means the person set forth in the “Collaborator JDC
Escalation Person Title” row of the Information Sheet. 

  

	1.21.	 “Collaborator Inventions” means all Inventions relating [***]. 

 

	1.22.	 “Combination” means the use or method of using the Collaborator Compound and the MSD Compound
[***]. 

  

	1.23.	 “Combination Arm(s)” means the portion of the Collaborator Clinical Trial where patients are
intended to receive the Collaborator Compound and the MSD Compound in Combination [***]. 

  

	1.24.	 “Compounds” means the Collaborator Compound and the MSD Compound. A
“Compound” means either the Collaborator Compound or the MSD Compound. 

  
 4 

	1.25.	 “Confidential Information” means any information (including personal data), Know-How or other proprietary information or materials furnished to a Receiving Party by or on behalf of a Disclosing Party in connection with this Agreement, except to the extent that such information or materials,
[***]: (i) was already known to the Receiving Party, other than under an obligation of confidentiality, at the time of disclosure by the Disclosing Party; (ii) was generally available to the public or otherwise part of the public domain at the
time of its disclosure to the Receiving Party; (iii) became generally available to the public or otherwise part of the public domain after its disclosure and other than through a breach of this Agreement by the Receiving Party; (iv) was
disclosed to the Receiving Party by a Third Party who had no obligation to the Disclosing Party not to disclose such information to others; or (v) was subsequently developed by the Receiving Party without use of the Disclosing Party’s
Confidential Information. MSD Clinical Data is deemed the Confidential Information of MSD (and MSD is the “Disclosing Party” and Collaborator the “Receiving Party” with respect to the same). Collaborator Clinical Data is deemed
the Confidential Information of Collaborator (and Collaborator is the “Disclosing Party” and MSD the “Receiving Party” with respect to the same). Joint Clinical Data is deemed to be the Confidential Information of both Parties.

  

	1.26.	 “Continuing Party” means the Party continuing prosecution or maintenance pursuant to
Section 10.4 (Declining to File, Prosecute or Maintain). 

  

	1.27.	 “Control” or “Controlled” means, with respect to particular information or
intellectual property, that the applicable Party or its Affiliate owns or has a license to such information or intellectual property and has the ability to grant a right, license or sublicense as provided for herein [***]. 

 

	1.28.	 “CTA” means an application to a Regulatory Authority for purposes of requesting the ability to
start or continue a clinical trial, including an “Investigational Medicinal Product Dossier” in the European Union. 

  

	1.29.	 “Data Protection Law” means any applicable data protection or privacy law to which a Party is
subject in connection with this Agreement. 

  

	1.30.	 “Data Protection Terms” means Exhibit C hereto, which ensures certain protections are in place
for the processing personal data in the performance of the MSD Compound Study and sets forth the Parties’ responsibilities for certain obligations, including addressing the rights of data subjects, ensuring a legal basis for processing personal
data, conducting appropriate data-protection impact assessments and prior consultations with relevant supervisory authorities, complying with all personal-data breach-notification obligations, and certain other compliance obligations under Data
Protection Law. 

  

	1.31.	 “Data Sharing Schedule” means the schedule attached hereto as Schedule I.

  
 5 

	1.32.	 “Defending Party” means a Party controlling the defense of an action pursuant to
Section 14.2.3 (Procedure). 

  

	1.33.	 “Delivery” means, with respect to a given quantity of (i) the MSD Compound, [***] and,
(ii) the Collaborator Compound, [***]. “Deliver” shall have a correlative meaning. 

  

	1.34.	 “Disclosing Party” means a Party (or its Affiliate) disclosing Confidential Information of
such Party hereunder. 

  

	1.35.	 “Effective Date” means the date set forth in the “Effective Date” row of the
Information Sheet. 

  

	1.36.	 “EMA” means the European Medicines Agency and any successor agency. 

 

	1.37.	 “Exclusions List” means: (i) List of Excluded Individuals and Entities on the U.S.
Department of Health and Human Services, Office of Inspector General (OIG) website including 42 U.S.C. 1320a-7 (https://www.oig.hhs.gov/exclusions/index.asp); (ii) the U.S. General Services
Administrator’s list of Parties Excluded from Federal Programs – System for Award Management (https://www.sam.gov/SAM/pages/public/searchRecords/search.jsf) and (iii) the debarment list promulgated under 21 U.S.C.335a
(https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/fda-debarment-list-drug-product-applications. 

 

	1.38.	 “FCPA” means the U.S. Foreign Corrupt Practices Act. 

 

	1.39.	 “FDA” means the United States Food and Drug Administration. 

 

	1.40.	 “Freedom-to-Operate
License” means a license to be granted by a Party to the other Party in the event this Agreement is amended or a new agreement is negotiated for the purpose of conducting a Subsequent Study in accordance with
Section 2.9. 

  

	1.41.	 “GCP” means the Good Clinical Practices officially published by EMA, FDA and the International
Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use that may be in effect from time to time and applicable to the testing of the Compounds. 

 

	1.42.	 “Government Official” means: (i) any officer or employee of a government or any
department, agency or instrument of a government; (ii) any Person acting in an official capacity for or on behalf of a government or any department, agency, or instrument of a government; (iii) any officer or employee of a company or
business owned in whole or part by a government; (iv) any officer or employee of a public international organization such as the World Bank or United Nations; (v) any officer or employee of a political party or any Person acting in an
official capacity on behalf of a political party; or (vi) any candidate for political office; who, in each of the foregoing cases (i) through (vi), when such Government Official is acting in an official capacity or in an official
decision-making role, has responsibility for performing regulatory inspections, government authorizations or licenses, or otherwise has the capacity to make decisions with the potential to affect the business of either Party. 

  
 6 

	1.43.	 “IND” means any Investigational New Drug Application as described in Title 21 of the U.S. Code
of Federal Regulations, Part 312. 

  

	1.44.	 “Information Sheet” means the table entitled Information Sheet set forth just before the
preamble to this Agreement. 

  

	1.45.	 “Inventions” means all inventions and discoveries, whether or not patentable, that are made,
conceived, or first actually reduced to practice by or on behalf of a Party, or by or on behalf of the Parties together: [***]. 

  

	1.46.	 “Joint Clinical Data” means all data (including raw data) and results generated by or on
behalf of either Party or at either Party’s direction, or by or on behalf of the Parties together or at their direction, in the course of the Combination Arm(s); provided however, that Joint Clinical Data does not include [***].

  

	1.47.	 “Joint Development Committee” or “JDC” means the committee to be established
by the Parties pursuant to Section 2.3 (Joint Development Committee; Managers). 

  

	1.48.	 “Joint Patent” means a Patent with respect to any Joint Invention. 

 

	1.49.	 “Joint Invention” means any Inventions relating to or covering the combined use of the
Collaborator Compound and the MSD Compound that are not MSD Inventions or Collaborator Inventions, [***]. 

  

	1.50.	 “Kit” means a single vial of MSD Compound, as detailed in the
pro-forma invoice that accompanies the MSD Compound for which MSD is entitled to reimbursement pursuant to Sections 6.10 (Manufacturing Costs) or 8.9.2
(Non-Conformance). 

  

	1.51.	 “Know-How” means any proprietary invention,
innovation, improvement, development, discovery, computer program, device, trade secret, method, know-how, process, technique or the like, including manufacturing, use, process, structural, operational and
other data and information, whether or not written or otherwise fixed in any form or medium, regardless of the media on which contained and whether or not patentable or copyrightable, that is not generally known or otherwise in the public domain.

  

	1.52.	 “Liability” means any loss, damage, reasonable costs and expenses (including reasonable
attorneys’ fees and expenses) incurred in connection with any claim, proceeding, or investigation by a Third Party arising out of [***]. 

  
 7 

	1.53.	 “Manufacture,” “Manufactured,” or “Manufacturing” means all
activities related to the manufacture of a Compound, including planning, purchasing, manufacture, processing, compounding, storage, filling, packaging, waste disposal, labeling, leafleting, testing, quality assurance, sample retention, stability
testing, release, dispatch and supply. 

  

	1.54.	 “Manufacturer’s Release” or “Release” has the meaning ascribed to
release of the MSD Compound in the Clinical Quality Agreement. 

  

	1.55.	 “Manufacturing Site” means the facilities where a Compound is Manufactured by or on behalf of
a Party. 

  

	1.56.	 “MSD” has the meaning set forth in the preamble to this Agreement.

  

	1.57.	 “MSD Background Patents” means any Patent Controlled by MSD or its Affiliate that claims or
covers the Combination and is not a Joint Patent. 

  

	1.58.	 “MSD Clinical Data” means all data (including raw data) and results generated by or on behalf
of either Party or at either Party’s direction, or by or on behalf of the Parties together or at their direction, in the course of the MSD Compound Arm(s), if any MSD Compound Arm(s) are included in the Collaborator Clinical Trial; provided
however, that MSD Clinical Data does not include [***]. 

  

	1.59.	 “MSD Compound” means pembrolizumab, a humanized anti-human
PD-1 monoclonal antibody, [***]. 

  

	1.60.	 “MSD Compound Arm(s)” means any portion of the Collaborator Clinical Trial where patients are
intended to receive the MSD Compound either alone or in combination with one or more treatments but not in Combination with the Collaborator Compound. 

  

	1.61.	 “MSD Compound Study” means the arms of the Collaborator Clinical Trial where patients are
intended to receive the MSD Compound either alone or in combination with one or more treatments (including the Collaborator Compound). The MSD Compound Study includes the Combination Arm(s) and any MSD Compound Arm(s) included in the Collaborator
Clinical Trial. 

  

	1.62.	 “MSD Compound Study Completion” means: (i) the date when the last patient enrolled
in the MSD Compound Study has completed their last study-related assessment for evaluation, excluding survival follow-up; or (ii) an alternative date as agreed to by the JDC in writing.

  

	1.63.	 “MSD Inventions” means all Inventions related to or covering the MSD Compound [***], and not
related to or covering the Collaborator Compound or a Collaborator Class Compound, and any improvements related thereto, regardless of whether such Invention was invented solely by MSD or Collaborator or jointly by the Parties.

  
 8 

	1.64.	 “NDA” means a New Drug Application, Biologics License Application, Marketing Authorization
Application, filing pursuant to Section 510(k) of the United States Federal Food, Drug and Cosmetic Act, or similar application or submission for a marketing authorization of a product filed with a Regulatory Authority to obtain marketing
approval for a biological, pharmaceutical or diagnostic product in a country or group of countries. 

  

	1.65.	 “Non-Conformance” means, with respect to a given unit
of Compound: (i) an event that deviates from an approved cGMP requirement with respect to the applicable Compound, such as a procedure, Specification, or operating parameter, or that requires an investigation to assess impact to the quality of
the applicable Compound; or (ii) that such Compound failed to meet the applicable representations and warranties set forth in Article 8 (Supply and Use of Compounds) or Section 13.2 (Compounds). “Non-Conforming” shall have a correlative meaning. 

  

	1.66.	 “Non-Pursuing Party” means a Party not pursuing the
filing, prosecution or maintenance of a Joint Patent pursuant to Section 10.4 (Declining to File, Prosecute or Maintain). 

  

	1.67.	 “Opting-out Party” means a Party that wishes to
discontinue the prosecution and maintenance of a Joint Patent pursuant to Section 10.4 (Declining to File, Prosecute or Maintain). 

  

	1.68.	 “Other Party” means a Party not controlling the defense of an action pursuant to
Section 14.2.3 (Procedure). 

  

	1.69.	 “Parties” and “Party” have the meanings set forth in the preamble to
this Agreement. 

  

	1.70.	 “Patent” means (a) a patent application, (b) any additions, priority applications,
divisions, continuations, and continuations-in-part of the patent application, and (c) all patents issuing on any of the foregoing patent applications, together
with all invention certificates, substitutions, reissues, reexaminations, registrations, supplementary protection certificates, confirmations, renewals, and extensions of any of (a), (b), or (c), in any and all jurisdictions worldwide.

  

	1.71.	 “PD-1 Antagonist” means any [***].

  

	1.72.	 “Person” means any entity, including any individual, sole proprietorship, partnership,
corporation, business trust, joint stock company, trust, unincorporated organization, association, limited liability company, institution, public benefit corporation, joint venture, or governmental entity. 

 

	1.73.	 “Pharmacovigilance Agreement” means the pharmacovigilance agreement to be executed by the
Parties pursuant to Section 2.6 (Pharmacovigilance Agreement). 

  

	1.74.	 “Project Manager” means the Project Managers to be designated by the Parties pursuant to
Section 2.3 (Joint Development Committee; Managers). 

  
 9 

	1.75.	 “Protocol” means the written documentation that describes the Collaborator Clinical Trial and
sets forth specific activities to be performed as part of the conduct of the Collaborator Clinical Trial. 

  

	1.76.	 “Pursuing Party” means a Party pursuing the filing, prosecution or maintenance of a Joint
Patent pursuant to Section 10.4 (Declining to File, Prosecute or Maintain). 

  

	1.77.	 “Receiving Party” means a Party (or its Affiliate) receiving Confidential Information of the
other Party hereunder. 

  

	1.78.	 “Regulatory Approvals” means, with respect to a Compound, any and all permissions (other than
the Manufacturing approvals) required to be obtained from any Regulatory Authority or other competent authority for the development, registration, importation and distribution of such Compound in any jurisdiction for use in the MSD Compound Study.

  

	1.79.	 “Regulatory Authorities” means the FDA, national regulatory authorities, the EMA, any
successor agency to the FDA or EMA and any agency or authority performing some or all of the functions of the FDA or EMA in any jurisdiction. 

  

	1.80.	 “Regulatory Documentation” means all submissions to Regulatory Authorities in connection with
the development of a Compound, including all INDs and amendments thereto, CTAs and amendments thereto, NDAs and amendments thereto, drug master files, correspondence with regulatory agencies, periodic safety update reports, adverse-event files,
complaint files, inspection reports and manufacturing records, in each case together with all supporting documents (including any documents that include Clinical Data). 

 

	1.81.	 “Related Agreements” means the Pharmacovigilance Agreement, and the Clinical Quality
Agreement. 

  

	1.82.	 “Related Entities” means, with respect to each of Collaborator and MSD, such Party’s
Affiliates and its and their directors, officers, employees and others acting on its or their behalf, including their respective Subcontractors. 

  

	1.83.	 “Relevant Agreements” has the meaning set forth in Section 6.10. 

 

	1.84.	 “Right of Reference” means the “right of reference” defined in Title 21 of the U.S.
Code of Federal Regulations, Part 314.3(b) or any non-U.S. equivalent including, with regard to a Party, allowing the applicable Regulatory Authority in a country to have access to relevant information and
data (by cross-reference, incorporation by reference or otherwise) contained in Regulatory Documentation filed with such Regulatory Authority with respect to a Party’s Compound. 

 

	1.85.	 “SAE” means a serious adverse event. 

  
 10 

	1.86.	 “Samples” means biological specimens collected from subjects participating in the MSD Compound
Study, including any urine, blood and tissue samples. 

  

	1.87.	 “Sample Testing” means the analyses to be performed by each Party using the applicable
Samples, as described in the Sample Testing Schedule. 

  

	1.88.	 “Sample Testing Results” means the data and results arising from the Sample Testing.

  

	1.89.	 “Sample Testing Schedule” means the schedule attached hereto as Schedule II.

  

	1.90.	 “Sensitive Information” means unpublished Joint Clinical Data, MSD Clinical Data, Sample
Testing Results generated by MSD and Confidential Information relating to MSD Inventions or the MSD Compound (but not information solely relating to a Collaborator Compound and not to the MSD Compound). 

 

	1.91.	 “Specifications” means the requirements to which a Compound must conform. The Specifications
for a Compound will be set forth in the certificate of analysis accompanying each batch of Compound supplied for use in the MSD Compound Study. 

  

	1.92.	 “Subcontractors” means any and all Third Parties to whom a Party delegates any of its
obligations hereunder. 

  

	1.93.	 “Subsequent Study” means a registrational study for the Combination in the same indication(s)
and line(s) of therapy as that included in the Combination Arm(s). 

  

	1.94.	 “Sunshine Act” shall mean the Physician Payments Sunshine Act as amended from time to time.

  

	1.95.	 “Term” means the term of this Agreement. 

 

	1.96.	 “Third Party” means any Person or entity other than Collaborator, MSD or their respective
Affiliates. 

  

	1.97.	 “Third-Party Infringement” means any actual or threatened infringement or misappropriation by
a Third Party of any Joint Patent or Joint Invention. 

  

	1.98.	 “Toxicity and Safety Data” means all clinical adverse-event information or patient-related
safety data [***]. 

  

	1.99.	 “Transparency Report” means a transparency report in connection with reporting payments and
other transfers of value made to health-care professionals, including investigators, steering-committee members, data-monitoring committee members, and consultants in connection with the MSD Compound Study in accordance with reporting requirements
under Applicable Law, including the Sunshine Act and state gift laws, and the European Federation of Pharmaceutical Industries and Associations Disclosure Code, and a Party’s applicable policies. 

  
 11 

	1.100.	 “VAT” means a value-added or similar tax. 

 

	1.101.	 “Violation” means that a Party or any of its officers or directors or any other personnel (or
other permitted agents of a Party performing activities hereunder) has been: (i) convicted of any of the felonies identified among the Exclusion Lists or (ii) identified or listed as having an active exclusion on any Exclusion List; or
(iii) listed by any US Federal agency as being suspended, proposed for debarment, debarred, excluded or otherwise ineligible to participate in Federal procurement or non-procurement programs, including
under any Exclusion List. 

 2.    PERFORMANCE OF THE AGREEMENT. RELATED AGREEMENTS. 

 

	2.1.	 The Collaborator Clinical Trial. Collaborator is conducting or intends to conduct the
Collaborator Clinical Trial, which Collaborator Clinical Trial has or is intended to have a Combination Arm(s). In addition, the Collaborator Clinical Trial may (or may not) have a Collaborator Compound Arm(s), an MSD Compound Arm(s), or both. The
term “Collaborator Clinical Trial” as used in this Agreement refers to the Collaborator Clinical Trial as a whole, including the Combination Arm(s), and any Collaborator Compound Arm(s) or MSD Compound Arm(s) that form or are
intended to form a part of the Collaborator Clinical Trial. The term “MSD Compound Study” refers to the Combination Arm(s) and any MSD Compound Arm(s) that form or are intended to form a part of the Collaborator Clinical Trial.
Collaborator Clinical Trial, Collaborator Compound Arm(s), Combination Arm(s), MSD Compound Arm(s) and MSD Compound Study all refer to such arms as are intended to be conducted in accordance with the Protocol, including the Protocol as may be
amended in accordance with Article 4 (PROTOCOL AND INFORMED CONSENT; CERTAIN COVENANTS). 

  

	2.2.	 Generally. Each Party shall: (i) contribute such resources as are necessary to conduct the
activities contemplated by this Agreement; and (ii) act in good faith in performing its obligations under this Agreement and each Related Agreement to which it is a Party. 

 

	2.3.	 Joint Development Committee; Managers; Escalation. 

 

	 	2.3.1.	 The Parties shall form the Joint Development Committee made up of an equal number of representatives of MSD and
Collaborator, which shall have responsibility for coordinating all regulatory and other activities under, and pursuant to, this Agreement (except for activities under, and pursuant to, Article 10 (INTELLECTUAL PROPERTY)). Representatives of MSD and
Collaborator on the JDC shall be entitled to one collective vote on behalf of each of MSD and Collaborator, respectively, on all matters upon which the JDC have the right to decide under this Agreement. Each Party shall designate a Project Manager
who shall be responsible for implementing and coordinating activities and facilitating the exchange of information between the Parties with respect to the MSD Compound Study and shall be entitled to attend meetings of the JDC. JDC members will be
agreed by both Parties. 

  
 12 

	 	2.3.2.	 The JDC shall meet a minimum of two (2) times per year, unless otherwise agreed by the JDC, to provide an
update on the progress of the MSD Compound Study. The JDC may meet in person or by means of teleconference, internet conference, videoconference or similar means. Prior to any such meeting, Collaborator’s Project Manager shall provide a written
update to MSD’s Project Manager and Alliance Manager containing information about the overall progress of the MSD Compound Study, recruitment status, interim analysis (if available), final analysis and other information relevant to the conduct
of the MSD Compound Study (and data relating to the Collaborator Clinical Trial reasonably requested by MSD and relevant to the MSD Compound Study). 

  

	 	2.3.3.	 In addition to a Project Manager, each Party shall designate an Alliance Manager who shall serve as the primary
point of contact for any issues arising under this Agreement and shall endeavor to ensure clear and responsive communication and the effective exchange of information between the Parties. The Alliance Managers shall have the right to attend all JDC
meetings and may bring to the attention of the JDC any matters either of them reasonably believes should be discussed and shall have such other responsibilities as the Parties may mutually agree. 

 

	 	2.3.4.	 In the event that (i) an issue arises and the Alliance Managers do not, after good faith efforts, reach
agreement on such issue, (ii) there is a decision to be made by the JDC on which the members of the JDC do not agree, or (iii) the Parties cannot agree on a matter in respect of the Protocol, the issue shall be elevated to the Senior Vice
President of Clinical Research for MSD and the Collaborator Escalation Contact. In the event such escalation does not result in resolution or consensus: (x) MSD shall have final decision-making authority with respect to issues solely related to
MSD Compound; and (y) Collaborator shall have final decision-making authority with respect to all other issues relating to the implementation of the Collaborator Clinical Trial. 

 

	2.4.	 Clinical Quality Agreement. The Parties will execute the Clinical Quality Agreement prior to any
supply of MSD Compound hereunder, and no later than [***] after the Effective Date. The Clinical Quality Agreement shall, among other things: (i) detail classification of any Non-Conforming MSD Compound;
(ii) include criteria for Manufacturer’s Release and related certificates and documentation; (iii) include criteria and timeframes for acceptance of MSD Compound; (iv) include procedures for the resolution of disputes regarding
any Non-Conforming MSD Compound; (v) detail procedures and rights with respect to audit and inspection rights for Manufacturing sites; and (vi) include provisions governing the recall of Compounds.
Quality matters and the Manufacture of the MSD Compound shall be governed by the terms of the Clinical Quality Agreement in addition to the relevant quality provisions of this Agreement. 

  
 13 

	2.5.	 Data Protection. The Parties will comply with the Data Protection Terms set forth on Exhibit C,
which are incorporated into and form a part of this Agreement. 

  

	2.6.	 Pharmacovigilance Agreement. The Parties will execute the Pharmacovigilance Agreement prior to
MSD Delivering MSD Compound to Collaborator hereunder. The Pharmacovigilance Agreement will: (i) include safety data exchange procedures; (ii) facilitate appropriate safety reviews; (iii) govern the coordination of collection,
investigation, reporting, and exchange of information concerning any adverse experiences, pregnancy reports, and any other safety information arising from or related to the use of the MSD Compound and Collaborator Compound in the MSD Compound Study;
and (iv) enable the Parties and their Affiliates to fulfill local and international regulatory reporting obligations to Regulatory Authorities, all of the foregoing in accordance with Applicable Law. For the avoidance of doubt, the obligations
to provide safety data under the Pharmacovigilance Agreement will be independent of any obligations to provide safety data pursuant to this Agreement. 

  

	2.7.	 Delegation of Obligations. Each Party shall have the right to delegate any portion of its
obligations hereunder only: (i) to such Party’s Affiliates; (ii) to Third Parties that are set forth on Schedule III as performing MSD Compound Study activities or as conducting Sample Testing for such Party; (iii) to the
extent related to the Manufacture of such Party’s Compound; and (iv) upon the other Party’s prior consent. Notwithstanding any delegation of its obligations hereunder, each Party shall remain solely and fully liable for the
performance of its Affiliates and Subcontractors under this Agreement. Each Party shall ensure that each of its Affiliates and Subcontractors performs such Party’s obligations pursuant to the terms of this Agreement. Each Party shall use
reasonable efforts to obtain and maintain copies of documents relating to the obligations performed by its Affiliates and Subcontractors that are required to be provided to the other Party under this Agreement. 

 

	2.8.	 Relationship. Without prejudice to Section 2.9 (Subsequent Study), this
Agreement does not create any obligation for either Party to provide any compound other than its Compound or to provide its Compound for any activities other than the MSD Compound Study. Except as expressly set forth in
Section 2.9 (Subsequent Study), nothing in this Agreement shall: [***] or (ii) create an exclusive relationship between the Parties with respect to any Compound. Each Party acknowledges and agrees that nothing in this
Agreement shall be construed as a representation or inference that the other Party will not develop for itself, or enter into business relationships with other Third Parties regarding, any products, programs, studies (including combination studies),
technologies or processes that are similar to or that may compete with the Combination or any other product, program, technology or process, [***] are not used or disclosed in connection therewith in violation of this Agreement. Notwithstanding the
foregoing, and notwithstanding any implication to the contrary in this Agreement, Collaborator shall have no right to include any PD-1 Antagonist other than the MSD Compound in the Collaborator Clinical Trial.
Collaborator and MSD have no obligation to renew this Agreement or apply this Agreement to any clinical trial other than the Collaborator Clinical Trial. Except as expressly set forth in Section 2.9 (Subsequent Study),
nothing in this Agreement obligates the Parties to enter into any agreement other than the Related Agreements now or in the future. 

  
 14 

	2.9.	 Subsequent Study. During the Term and for a period of [***] thereafter, either Party shall have
the option to propose amending this Agreement (and the Related Agreements as necessary) or negotiating a new agreement, as appropriate, for the purpose of conducting a Subsequent Study. During such time period, Collaborator must offer MSD the option
of participating in a Subsequent Study no less than [***] prior to entering into an agreement with a Third Party to conduct a registrational study of [***]. Following receipt of a proposal for a Subsequent Study, the Parties shall negotiate in good
faith the terms of such amendment or new agreement. Neither Party will have any obligation to agree upon the details of or execute any such amendment or agreement; provided, however, in the event this Agreement is amended or a new agreement is
negotiated for the purpose of conducting a Subsequent Study, the Parties shall grant to each other a non-exclusive, worldwide, royalty-free, fully paid-up, transferable,
and sublicensable license [***](“Freedom-to-Operate License”). Notwithstanding such
Freedom-to-Operate License, in no event shall:[***]. 

3.    CONDUCT OF THE MSD COMPOUND STUDY. 
  

	3.1.	 Sponsor. Collaborator shall act as the sponsor of the Collaborator Clinical Trial under its own
IND or CTA for the Collaborator Compound with a Right of Reference to the IND or CTA of the MSD Compound as described in Section 3.5 (Regulatory Matters); provided, however, that in no event shall Collaborator file an
additional IND or CTA for the MSD Compound Study unless required by Regulatory Authorities to do so. If a Regulatory Authority requests such an additional IND or CTA for the MSD Compound Study, the Parties shall meet and agree on an approach to
address such requirement. 

  

	3.2.	 Clinical Safety Data Review. If the Information Sheet indicates that this Agreement contains a
safety gate (i.e. “Yes” is selected for the Safety Gate (Yes/No) row), then this Section 3.2 (Clinical Safety Data Review) shall apply to this Agreement. If “No” is selected, for such Safety Gate row, then this
Section 3.2 (Clinical Safety Data Review) shall be deemed omitted from this Agreement and shall not apply. [***] 

  
 15 

	3.3.	 Performance. Collaborator shall ensure that the MSD Compound Study and all related activities are
performed in accordance with this Agreement, the Protocol and all Applicable Law, including GCP. 

  

	3.4.	 Debarred Personnel; Exclusions Lists. [***]. 

 

	3.5.	 Regulatory Matters. Collaborator shall: (i) obtain all Regulatory Approvals from all
Regulatory Authorities, ethics committees and institutional review boards with jurisdiction over the MSD Compound Study prior to its initiation; and (ii) follow all directions from any such Regulatory Authorities, ethics committees and
institutional review boards. [***] with a Regulatory Authority regarding matters related to the MSD Compound Study or the MSD Compound and to collaborate on questions posed to Regulatory Authorities regarding design and conduct of the MSD Compound
Study. If a Right of Reference is necessary for the conduct of the MSD Compound Study in a given country, each Party shall provide a cross-reference letter or similar communication to the applicable Regulatory Authority as needed to effectuate the
Right of Reference. [***]. MSD shall authorize the FDA and other applicable Regulatory Authorities to cross-reference the appropriate MSD Compound INDs and CTAs to provide data access to Collaborator as necessary to conduct the MSD Compound Study.
If MSD’s CTA is not available in a given country, [***]. 

  

	 	3.5.1.	 Investigator’s Brochure for MSD Compound. MSD shall provide Collaborator with the current
investigator’s brochure for the MSD Compound promptly following the Effective Date and before the initiation of the MSD Compound Study and any material updates or changes to the investigator’s brochure for the MSD Compound within [***] of
internal approval during the Term for use by Collaborator as needed for regulatory and safety purposes. All versions of MSD’s investigator’s brochure for the MSD Compound provided by MSD to Collaborator shall be MSD Confidential
Information. 

  

	3.6.	 Documentation. Collaborator shall maintain reports and all related documentation in good
scientific manner and in compliance with Applicable Law. Collaborator shall provide to MSD all Collaborator Clinical Trial information and documentation reasonably requested by MSD to enable MSD to: (i) comply with any of its legal, regulatory
or contractual obligations, or any request by any Regulatory Authority related to the MSD Compound; and (ii) determine whether the MSD Compound Study has been performed in accordance with this Agreement. 

  
 16 

	3.7.	 Copies. Collaborator shall provide to MSD copies of all Joint Clinical Data and any MSD Clinical
Data in electronic form or other mutually agreeable alternate form and on the timelines specified in the Data Sharing Schedule or mutually agreed; provided, however, that a complete copy of the Joint Clinical Data and any MSD Clinical Data shall be
provided to MSD no later than [***] following MSD Compound Study Completion or any sooner termination of this Agreement. Collaborator shall ensure that: (i) all patient authorizations and consents required under Applicable Law in connection
with the Collaborator Clinical Trial permit such sharing of Joint Clinical Data and any MSD Clinical Data with MSD; and (ii) it complies with Applicable Law in transferring personal data hereunder. 

 

	3.8.	 Sample Testing. 

 

	 	3.8.1.	 Collaborator shall provide Samples to MSD as specified in the Protocol and as agreed to by the Joint
Development Committee. Each Party shall use the Samples only for Sample Testing in accordance with the Sample Testing Schedule and the Protocol. [***]. 

  

	 	3.8.2.	 Except to the extent otherwise expressly agreed, each Party may use and disclose unpublished Sample Testing
Results owned by and shared by the other Party in accordance with the Sample Testing Schedule [***]. 

  

	3.9.	 Ownership and Use of Joint Clinical Data. 

 

	 	3.9.1.	 [***]. Collaborator shall maintain the Joint Clinical Data [***] in its internal database; provided, however,
that at all times during the Term and for [***] thereafter, Collaborator shall grant MSD access to all Joint Clinical Data[***]. If MSD requests access to Collaborator Clinical Data to evaluate the safety or performance of the Combination or to
register the MSD Compound in the Combination, Collaborator shall promptly provide MSD with such data. 

  

	 	3.9.2.	 [***]. 

  

	 	3.9.3.	 Notwithstanding the foregoing, before publication or presentation of a summary of the Joint Clinical Data in
accordance with Section 12.2 (Publication), [***]; provided, however, that the foregoing shall not limit or restrict either Party’s ability to[***]. [***]. For clarity, following publication of the Joint Clinical Data
in accordance with Article 12, the restrictions set forth in this Section 3.9.3 shall no longer apply with respect to [***]. 

  

	 	3.9.4.	 Notwithstanding anything to the contrary in this Section 3.9 (Ownership and Use of
Joint Clinical Data), Collaborator may: [***]; and (z) Collaborator must notify MSD at least [***] before such disclosure of the reasons for the planned disclosure and provide MSD with a copy of the Clinical Data (and any related summaries or
analyses) to be disclosed. Collaborator will consider MSD’s comments on such Clinical Data, summaries and analyses. 

  
 17 

	3.10.	 Regulatory Submission. It is understood and acknowledged by the Parties that positive
Clinical Data may be used to obtain label changes for the Compounds. 

  

	3.11.	 Certain Memoranda and Reports. Promptly following MSD Compound Study Completion, Collaborator
shall provide to MSD an electronic draft of the top-line results memorandum and an electronic draft of the final report of the results of the MSD Compound Study. MSD shall have [***] after receipt of such
results memorandum and [***] after receipt of such final report to provide comments thereon. Collaborator shall consider any comments provided by MSD on either document and shall not include any statements in either document relating to [***].
Collaborator shall deliver to MSD a final version of each such document promptly following finalization thereof. 

  

	3.12.	 Licensing. 

 

	 	3.12.1.	 Nothing in this Agreement shall prohibit or restrict a Party from licensing, assigning or transferring to an
Affiliate or Third Party such Party’s Compound[***] owned solely by such Party. 

  

	 	3.12.2.	 A Party may license, assign or transfer to an Affiliate or Third Party, subject to any obligations or
restrictions set forth in this Agreement, such Party’s interest in the [***] owned jointly by the Parties or [***], and, in connection therewith, [***] owned by the other Party, solely to the extent such licensee, assignee or transferee agrees
to be bound by the terms of this Agreement with respect to the licensed, assigned or transferred interest which agreement shall be in writing with respect to any license, assignment or transfer to a Third Party. 

4.    PROTOCOL AND INFORMED CONSENT; CERTAIN COVENANTS. 
  

	4.1.	 Protocol. The agreed initial Protocol, or a synopsis, and any agreed draft statistical analysis
plan for the MSD Compound Study or Collaborator Clinical Trial are attached hereto as Exhibit A. Collaborator shall: (i) provide a draft of the Protocol (and any subsequent revisions thereof) to MSD for MSD’s review and comment;
(ii) consider any changes to the draft of the Protocol requested by MSD; (iii) incorporate any changes requested by MSD with respect to MSD Compound; and (iv) submit the draft Protocol to MSD for final approval. The country or
countries in which the MSD Compound Study will be performed will be reviewed and agreed upon by the Parties before MSD Compound Study initiation and any changes thereto will be subject to review and approval of MSD; provided, however that MSD will
be deemed to have consented to Collaborator performing the MSD Compound Study in the countries identified on Exhibit D. To the extent the Parties cannot agree regarding the contents of the Protocol for final approval: (x) Collaborator
shall have final decision-making authority with respect to matters in the Protocol solely related to [***]; (y) MSD shall have final decision-making authority with respect to matters in the Protocol related [***]; and (z) all other matters
in respect of the Protocol on which the Parties cannot agree shall be resolved in accordance with Section 2.3.4 (Joint Development Committee; Managers; Escalation). Notwithstanding anything to the contrary contained herein,
[***], in its sole discretion, shall have the sole right to determine [***] and shall have the final decision on all matters relating [***] and any information regarding [***] included in the Protocol. 

  
 18 

	4.2.	 Informed Consent. Collaborator shall prepare the patient informed-consent form for the MSD
Compound Study (which shall include provisions regarding the use of Samples in Sample Testing) in consultation with MSD (it being understood and agreed that the portion of the informed-consent form relating to the Sample Testing of the MSD Compound
shall be provided to Collaborator by MSD and adopted by Collaborator). 

  

	4.3.	 Changes to Protocol or Informed Consent. Any proposed changes to: (i) the approved final
Protocol (other than changes that are solely related to Collaborator Compound); or (ii) the informed consent form relating to the MSD Compound, including Sample Testing of the MSD Compound, shall be made [***]. 

 

	4.4.	 Transparency Reporting. Collaborator is solely responsible for reporting payments and other
transfers of value, (including supply of MSD Compound), made to health-care professionals, including investigators, steering-committee members, data-monitoring committee members, and consultants in connection with the MSD Compound Study in
accordance with reporting requirements under Applicable Law, including the Sunshine Act and state gift laws, and the European Federation of Pharmaceutical Industries and Associations Disclosure Code, and Collaborator’s applicable policies.
Promptly after the Effective Date, Collaborator will notify MSD of Collaborator’s point of contact for purposes of receiving information from MSD pursuant to this Section 4.4, along with such contact’s full name,
email address, and telephone number. Collaborator may update such contact from time to time by notifying MSD pursuant to Article 22 (NOTICES). Where applicable, MSD will provide to such Collaborator contact all information regarding the value
of the MSD Compound provided for use in the MSD Compound Study as required for such reporting. In the event that the value of the MSD Compound provided pursuant to this Section 4.4 materially changes, MSD shall notify
Collaborator of such revised value and the effective date thereof. 

  

	 	4.4.1.	 Periods Collaborator is Not Required to Report. With respect to any annual reporting period in which
[***], Collaborator will: (i) notify MSD within [***] after the commencement of such reporting period that Collaborator is not so required; and (ii) during such reporting period Collaborator will track and provide to MSD data regarding
“indirect” payments or other transfers of value by Collaborator to health care professionals to the extent such payments or other transfers of value were required, instructed, directed or otherwise caused by MSD pursuant to this Agreement
in the format requested by MSD and provided on a basis to be agreed upon by the Parties. Collaborator represents and warrants that any data provided by Collaborator to MSD pursuant to this Section 4.4 will be complete and
accurate to the best of Collaborator’s knowledge. 

  
 19 

	4.5.	 Financial Disclosure. To the extent required by Applicable Law, Collaborator will [***].

 5.    ADVERSE EVENT REPORTING. 
  

	5.1.	 Pharmacovigilance. Collaborator will be solely responsible for safety reporting for the
Collaborator Clinical Trial and related activities, all in accordance with Applicable Law. 

  

	5.2.	 Transmission of SAEs. Collaborator will transmit to MSD all SAEs from the MSD Compound Study as
set forth below. All cases will be transmitted on a CIOMS-1 form in English. 

  

	 	5.2.1.	 For fatal and life-threatening SAEs, Collaborator will transmit a processed case within [***] after receipt by
Collaborator of notice of such SAEs. 

  

	 	5.2.2.	 For all other SAEs and newly diagnosed cancer, Collaborator will transmit a processed case within [***] after
receipt by Collaborator of notice of such SAEs. 

  

	 	5.2.3.	 Cases of disease progression will be handled as outlined in the Protocol, and if the Protocol specifies that
such cases are collected as SAEs, Collaborator will transmit such cases to MSD within the applicable timeframe set forth in Section 5.2.1 or Section 5.2.2. 

 

	 	5.2.4.	 For all other reportable information that includes: (i) overdose, exposure during pregnancy or lactation;
and (ii) cases of potential drug-induced liver injury where the patient was exposed to the MSD Compound (if required to be collected or identified per the Protocol), Collaborator will transmit a processed case within [***] after receipt by
Collaborator of such information. 

 6.    TERM AND TERMINATION. 

 

	6.1.	 Term. The Term shall commence on the Effective Date and shall continue in full force and effect
until delivery of final documents by Collaborator pursuant to Section 3.11 (Certain Memoranda and Reports), unless terminated earlier by either Party pursuant to this Article 6. 

  
 20 

	6.2.	 MSD Termination for Unsafe Use. In the event MSD notifies Collaborator that [***], MSD may
terminate this Agreement and the supply of the MSD Compound by notice to Collaborator [***]. 

  

	6.3.	 Termination for Breach; Continuation in the Event of Breach. 

 

	 	6.3.1.	 Either Party may terminate this Agreement by notice with immediate effect if the other Party commits a material
breach of this Agreement and such material breach continues for [***] after receipt of notice thereof from the non-breaching Party; provided that if such material breach cannot reasonably be cured within
[***], the breaching Party shall be given a reasonable period of time to cure such breach; provided further, that if such material breach is incapable of cure, then the notifying Party may terminate this Agreement by notice effective at the
expiration of such [***] cure period. Either Party shall have the right to terminate this Agreement by notice to the other Party with immediate effect if such other Party fails to perform any of its obligations under
Section 13.4 (Anti-Corruption) or breaches any representation or warranty contained in Section 13.4 (Anti-Corruption). 

 

	 	6.3.2.	 In addition: [***]. 

  

	 	6.3.3.	 Alternatively, [***]. 

 

	6.4.	 Termination for Patient Safety. If either Party determines [***] that the MSD Compound Study or
Collaborator Clinical Trial may unreasonably adversely affect patient safety, such Party shall promptly notify the other Party of such determination. The Party receiving such notice may propose modifications to the MSD Compound Study or Collaborator
Clinical Trial to address the safety issue identified by the other Party and, if the notifying Party agrees, shall act to immediately implement such modifications; provided, however, that if the notifying Party, in its sole discretion, believes that
there is imminent danger to patients, such Party need not wait for the proposed modifications and may instead terminate this Agreement immediately by notice to the other Party with immediate effect. Furthermore, the notifying Party may terminate
this Agreement by notice to the other Party with immediate effect if, in its sole discretion, it believes that the modifications proposed by the other Party will not resolve the patient safety issue. 

 

	6.5.	 Termination for Regulatory Action; Other Reasons. Either Party may terminate this Agreement by
notice to the other Party with immediate effect in the event that any Regulatory Authority takes any action, or raises any objection, that prevents the terminating Party from supplying its Compound for purposes of the MSD Compound Study.
Additionally, either Party shall have the right to terminate this Agreement by notice with immediate effect to the other Party in the event that it determines in its sole discretion to withdraw any applicable Regulatory Approval for its Compound or
to discontinue development of its Compound for medical, scientific or legal reasons. 

  
 21 

	6.6.	 Return of MSD Compound. If Collaborator remains in possession (including through any Affiliate or
Subcontractor) of MSD Compound at the time this Agreement expires or is terminated, Collaborator shall promptly return or destroy all unused MSD Compound as instructed by MSD in its sole discretion. Collaborator shall provide certification of any
requested destruction. 

  

	6.7.	 Survival. The provisions of [***] shall survive the expiration or termination of this Agreement.

  

	6.8.	 No Prejudice. Termination of this Agreement shall be without prejudice to any claim or right of
action of either Party for any breach of this Agreement. Except as set forth in Section 6.10 (Manufacturing Costs) and the foregoing sentence, the non-terminating Party shall have no
claim against the terminating Party for compensation for any loss of whatever nature by virtue of the termination of this Agreement. 

  

	6.9.	 Confidential Information. Upon expiration or termination of this Agreement, each Party and its
Affiliates shall promptly return to the Disclosing Party [***] furnished to the Receiving Party; provided, however that the Receiving Party may retain one copy of such Confidential Information in its confidential files, solely for purposes of
exercising the Receiving Party’s rights hereunder, satisfying its obligations hereunder or complying with any legal proceeding or requirement with respect thereto, and provided further that the Receiving Party shall not be required to erase
electronic files created in the ordinary course of business during automatic system back-up procedures pursuant to its electronic record retention and destruction practices that apply to its own general
electronic files and information so long as such electronic files are: (i) maintained only on centralized storage servers (and not on personal computers or devices); (ii) not accessible by any of its personnel (other than its information
technology specialists); and (iii) not otherwise accessed subsequently except with the written consent of the Disclosing Party or as required by law or legal process. Such retained copies of Confidential Information shall remain subject to the
confidentiality and non-use obligations herein. 

  

	6.10.	 Manufacturing Costs. In the event of termination by MSD pursuant to
Section 6.2 (Termination for Unsafe Use) or Section 6.3 (Termination for Breach), or in the event that MSD notifies Collaborator of a material breach of this Agreement or another Clinical Trial
Collaboration and Supply Agreement between the Parties involving the MSD Compound but elects to continue this Agreement or such other Clinical Trial Collaboration and Supply Agreement in lieu of termination in accordance with
Section 6.3.3, MSD shall be entitled to reimbursement by Collaborator for all MSD Compound provided pursuant to [***]; provided, that the aggregate amount of reimbursement payable to MSD under this
Section 6.10 for the MSD Compound provided pursuant to [***] shall not exceed $[***]. 

  
 22 

 7.    COSTS. 

[***]. 
 8.    SUPPLY AND
USE OF COMPOUNDS. 
  

	8.1.	 Supply of the Compounds. Subject to the terms and conditions of this Agreement, each of
Collaborator and MSD will use commercially-reasonable efforts to supply, or cause to be supplied, its Compound in the quantities and on the timelines set forth in Exhibit B, for use in the MSD Compound Study. If a change to the Protocol in
accordance with Article 4 (PROTOCOL AND INFORMED CONSENTS; CERTAIN COVENANTS) requires an increase of the quantity of MSD Compound to be provided of more than [***] or affects the timing for such quantities, the Parties shall amend Exhibit
B to reflect such changes. Each Party shall also provide the other Party a contact person for the supply of its Compound under this Agreement. Notwithstanding the foregoing, or anything to the contrary herein, if a Party is: (i) not
supplying its Compound in accordance with the terms of this Agreement, then the other Party shall have no obligation to supply its Compound; or (ii) allocating under Section 8.10 (Shortage; Allocation), then the other
Party may allocate proportionally. 

  

	8.2.	 Manufacturing Delay. Each Party shall notify the other Party as promptly as possible in the event
of any Manufacturing delay that is likely to adversely affect supply of its Compound hereunder. 

  

	8.3.	 Compound Commitments. Each Party agrees, at its own cost, to Manufacture and supply its Compound
in accordance with this Agreement and the Related Agreements. Without limiting the foregoing, each Party is responsible for obtaining all regulatory approvals (including facility licenses) that are required to Manufacture its Compound in accordance
with Applicable Law (provided that Collaborator shall be responsible for obtaining Regulatory Approvals for the MSD Compound Study as set forth in Section 3.5 (Regulatory Matters)). 

 

	8.4.	 Minimum Shelf Life Requirements. Each Party shall use commercially reasonable efforts to supply
its Compound hereunder with an adequate remaining shelf life at the time of Delivery to meet the MSD Compound Study requirements. 

  

	8.5.	 Provision of Compounds. 

  
 23 

	 	8.5.1.	 MSD will Deliver the MSD Compound to the location specified by Collaborator. Title for the MSD Compound shall
transfer from MSD to Collaborator at Delivery. All costs associated with the subsequent transportation, warehousing and distribution of MSD Compound shall be borne by Collaborator. Collaborator will, or will cause its designee to: (i) take
Delivery of the MSD Compound supplied hereunder; (ii) perform the acceptance (including testing) procedures allocated to it under the Clinical Quality Agreement; (iii) subsequently label and package the MSD Compound (in accordance with
Section 8.6 (Labeling and Packaging; Use, Handling and Storage)); and promptly ship the MSD Compound to the MSD Compound Study sites for use in the MSD Compound Study, in compliance with Applicable Law and the Clinical
Quality Agreement; (iv) keep complete and accurate records pertaining to the use and disposition of MSD Compound, including records relating to its storage, shipping (cold chain), in-transport temperature
recorder(s), receipt verification, chain-of-custody activities and usage and inventory reconciliation; (v) make the records described in subsection (iv) and
such other documentation as may be reasonably requested by MSD available for review by MSD for the purpose of conducting investigations for the determination of MSD Compound safety or efficacy and Collaborator’s compliance with this Agreement
with respect to the MSD Compound. 

  

	 	8.5.2.	 Collaborator is solely responsible for supplying (including all Manufacturing, acceptance and release testing)
the Collaborator Compound for the Collaborator Clinical Trial and the subsequent handling, storage, transportation, warehousing and distribution of all such Collaborator Compound. Collaborator shall ensure that all such activities are conducted in
compliance with Applicable Law and, with respect to the MSD Compound Study, the Clinical Quality Agreement. 

  

	8.6.	 Labeling and Packaging; Use, Handling and Storage. 

 

	 	8.6.1.	 The Parties’ obligations with respect to the labeling and packaging of the MSD Compound are as set forth
in the Clinical Quality Agreement. MSD shall provide the MSD Compound to Collaborator in the form of [***], and Collaborator shall label, package, use, store, transport, handle and dispose of the MSD Compound in accordance with MSD’s written
instructions and the terms and conditions of the Clinical Quality Agreement and Applicable Law. 

  

	 	8.6.2.	 Collaborator shall: (i) use the MSD Compound solely for purposes of performing the MSD Compound Study; and
(ii) not use the MSD Compound in any manner that is inconsistent with this Agreement or for any commercial purpose. Collaborator shall not reverse engineer, reverse compile, disassemble or otherwise attempt to derive the composition or
underlying information, structure or ideas of the MSD Compound, and in particular shall not analyze the MSD Compound by physical, chemical or biochemical means except as necessary to perform its obligations under the Clinical Quality Agreement.

  
 24 

	8.7.	 Product Specifications. A certificate of analysis shall accompany each shipment of the MSD
Compound to Collaborator. Upon request, Collaborator shall provide MSD with a certificate of analysis covering [***] shipment of Collaborator Compound used in the MSD Compound Study. 

 

	8.8.	 Changes to Manufacturing. Each Party may make changes from time to time to its Compound or the
Manufacturing Site, provided that such changes shall be in accordance with the Clinical Quality Agreement. 

  

	8.9.	 Product Testing; Nonconformance. 

 

	 	8.9.1.	 After Manufacturer’s Release. After Manufacturer’s Release of the MSD
Compound and concurrently with Delivery of the MSD Compound to Collaborator, MSD shall provide Collaborator with the documentation described in the Clinical Quality Agreement. Collaborator shall conduct the acceptance procedures under the Clinical
Quality Agreement within the time frames set forth therein. Collaborator shall be solely responsible for taking all steps necessary to determine that MSD Compound or Collaborator Compound, as applicable, is suitable for release before making such
Compounds available for human use, and MSD shall assist Collaborator as Collaborator reasonably requests in making such determination for the MSD Compound. Collaborator shall be responsible for storage and maintenance of the MSD Compound until it is
tested and released, which storage and maintenance shall be in compliance with: (i) the Specifications for the MSD Compound, (ii) the Clinical Quality Agreement, (iii) Applicable Law, and (iv) any specific storage and maintenance
requirements as may be provided by MSD from time to time. Collaborator shall be responsible for any failure of the MSD Compound to meet the Specifications to the extent caused after Delivery to Collaborator hereunder. 

 

	 	8.9.2.	 Non-Conformance. 

 

	 	8.9.2.1.	 In the event that either Party becomes aware that any Compound may have a
Non-Conformance, despite testing and quality assurance activities (including any activities conducted by the Parties under Section 8.9.1 (After Manufacturer’s Release)), such
Party shall immediately notify the other Party. Notification related to MSD Compound shall be in accordance with the Clinical Quality Agreement. MSD shall investigate any Non-Conformance of the MSD Compound in
accordance with the Clinical Quality Agreement. 

  

	 	8.9.2.2.	 In the event that all or any portion of any proposed or actual shipment of the MSD Compound is agreed to be Non-Conforming at the time of Delivery to Collaborator then MSD shall replace any such Non-Conforming MSD Compound that has not been administered. [***] with respect to any
MSD Compound that is found to be Non-Conforming at the time of Delivery shall be: [***]. 

  
 25 

	 	8.9.2.3.	 Collaborator shall be responsible for, and MSD shall have no obligation or liability with respect to, any
Collaborator Compound that is found to have a Non-Conformance. Collaborator shall replace any such Collaborator Compound that has not been administered. [***] with respect to any Collaborator Compound that is
found to have a Non-Conformance at the time of Delivery shall be: [***]. 

  

	 	8.9.3.	 Resolution of Discrepancies. Disagreements regarding any determination of
Non-Conformance by Collaborator shall be resolved in accordance with the Clinical Quality Agreement or, in situations where the Clinical Quality Agreement does not apply, Section 21
(GOVERNING LAW; DISPUTE RESOLUTION) of this Agreement. 

  

	8.10.	 Shortage; Allocation. If a Party believes in good faith that it will not be able to fulfill its
supply obligations hereunder because its Compound is in short supply, such Party will provide prompt written notice to the other Party of such shortage, the shipments of Compound hereunder expected to be impacted and the quantity of its Compound
that such Party reasonably determines it will be able to supply and the Parties will promptly discuss the situation (including allocation of Compound supplied hereunder within the MSD Compound Study). The Party experiencing the shortage shall [***].

  

	8.11.	 Quality Control. Each Party shall implement and perform operating procedures and controls for
sampling, stability and other testing of its Compound, and for validation, documentation and release of its Compound and such other quality-assurance and quality-control procedures as are required by the Specifications, cGMPs and (with respect only
to the MSD Compound) the Clinical Quality Agreement. 

  

	8.12.	 VAT. Where MSD is treated as making a supply of goods in a particular jurisdiction [***] for VAT
purposes, and Collaborator is treated as receiving such supply in the same jurisdiction, thus resulting in an amount of VAT being properly chargeable on such supply, Collaborator shall be obliged to pay to MSD the amount of VAT properly chargeable
on such supply. Collaborator shall pay such VAT to MSD on receipt of a valid VAT invoice from MSD issued in accordance with the laws and regulations of the jurisdiction in which the VAT is properly chargeable. MSD will: (i) determine, in
accordance with Applicable Law, the value of the supply that has been made and, as a result, the corresponding amount of VAT that is properly chargeable; and (ii) provide Collaborator any information or copies of documents in MSD’s
Control as are reasonably necessary for VAT purposes to evidence that such supply will take, or has taken, place in the same jurisdiction. 

  
 26 

 9.    CONFIDENTIALITY. 

 

	9.1.	 Confidential Information. Subject to Section 13.4.8, Collaborator and
MSD agree to hold in confidence all Confidential Information of the other Party and use such Confidential Information only to fulfill its obligations or exercise its rights hereunder. Without limiting the foregoing, the Receiving Party may not,
without the prior written permission of the Disclosing Party, disclose any Confidential Information of the Disclosing Party to any Third Party except to the extent such disclosure is: (i) required by Applicable Law; (ii) pursuant to the
terms of this Agreement; or (iii) necessary for the conduct of the MSD Compound Study, and in each case (i) through (iii) provided that the Receiving Party shall provide reasonable advance notice to the Disclosing Party before making such
disclosure. For the avoidance of doubt, Collaborator may, without MSD’s consent, disclose Confidential Information to clinical trial sites and clinical trial investigators performing the MSD Compound Study, the data safety monitoring and
advisory boards relating to the MSD Compound Study, and Regulatory Authorities working with Collaborator on the MSD Compound Study, in each case as necessary for the performance of the MSD Compound Study and provided that such Persons (other than
governmental entities) are bound by an obligation of confidentiality at least as stringent as the obligations contained herein. 

  

	9.2.	 Inventions. Notwithstanding the foregoing: (i) Inventions that constitute Confidential
Information and are jointly owned by the Parties shall constitute the Confidential Information of both Parties and each Party shall have the right to use and disclose such Confidential Information in accordance with Articles 10 (INTELLECTUAL
PROPERTY), 11 (REPRINTS; REFERENCES IN PUBLICATION) and 12 (PUBLICATIONS; PRESS RELEASES); and (ii) Inventions that constitute Confidential Information and are solely owned by one Party shall constitute the Confidential
Information of that Party and such Party shall have the right to use and disclose such Confidential Information in accordance with Articles 10 (INTELLECTUAL PROPERTY), 11 (REPRINTS; REFERENCES IN PUBLICATION) and 12
(PUBLICATIONS; PRESS RELEASES). 

  

	9.3.	 Personal Identifiable Data. All Confidential Information containing personal identifiable data
shall be handled in accordance with all applicable data-protection and privacy laws, rules and regulations. 

  

	9.4.	 Publicity/Use of Names. Except as set forth in Section 12.3 (Press
Releases), no disclosure of the existence or terms of this Agreement may be made by either Party, and no Party shall use the name, trademark, trade name or logo of the other Party, its Affiliates or their respective employee(s) in any publicity,
promotion, news release or disclosure relating to this Agreement or its subject matter without the prior express written permission of such Person, except as may be required by Applicable Law. 

  
 27 

 10.    INTELLECTUAL PROPERTY. 

 

	10.1.	 Joint Ownership. [***]. 

 

	10.2.	 Right to Exploit. [***]. 

 

	10.3.	 Prosecution. [***]. 

 

	10.4.	 Declining to File, Prosecute or Maintain. [***]. 

 

	10.5.	 Prohibition of Patenting. Except as expressly provided in Section 10.3
(Prosecution) and in furtherance and not in limitation of Section 9.1 (Confidential Information), each Party agrees not to file or prosecute a Patent based on the other Party’s Confidential Information, and to give no
assistance to any Third Party for such Patent, in each case without the other Party’s prior written consent. 

  

	10.6.	 Patent Enforcement. 

 

	 	10.6.1.	 Each Party shall promptly notify the other of any Third-Party Infringement of which such Party becomes aware.

  

	 	10.6.2.	 [***] shall have the first right to initiate legal action to enforce all Joint Patents and Joint Inventions
against Third-Party Infringement [***] or to defend any declaratory judgment action relating thereto, at its sole expense. In the event that [***] fails to initiate or defend such action by the earlier of: (i) [***] after first being notified or
made aware of such Third-Party Infringement; and (ii) [***] before the expiration date for initiating or defending such action, [***] shall have the right to initiate or defend such action at its sole expense. 

 

	 	10.6.3.	 [***] shall have the first right to initiate legal action to enforce all Joint Patents and Joint Inventions
against Third-Party Infringement [***] or to defend any declaratory judgment action relating thereto, at its sole expense. In the event that [***] fails to initiate or defend such action by the earlier of: (i) [***] after first being notified or
made aware of such Third-Party Infringement; and (ii) [***] before the expiration date for initiating or defending such action, Collaborator shall have the right to do so at its sole expense. 

 

	 	10.6.4.	 [***] or to defend any declaratory judgment action relating thereto, and shall [***]. Notwithstanding the
foregoing, either Party shall have the right to opt-out of controlling such legal action by providing written notice to the other Party by the earliest of: (i) [***] after first being noticed of such
Third-Party Infringement; (ii) [***] before the expiration date for filing such action; (iii) [***] before the expiration date for filing an answer to a complaint in a declaratory judgment action; and (iv) [***] after notice is received, by one
Party from other Party, informing such receiving Party that an application has been filed with the U.S. Food & Drug Administration under Section 351(k) of the U.S. Public Health Services Act (42 U.S.C. 262(k)) seeking approval of a
biosimilar or interchangeable biological product of the MSD Compound (when MSD is notifying party) or the Collaborator Compound (if Collaborator Compound is a biological product and Collaborator is notifying Party), whichever comes first.

  
 28 

	 	10.6.5.	 If one Party brings any prosecution or enforcement action or proceeding against a Third Party with respect to
any [***], the other Party agrees to be joined as a party plaintiff if requested and to give the first Party reasonable assistance and authority to file and prosecute the suit. The Party bringing suit shall bear its own costs and expenses, and any
damages or other monetary awards recovered shall be shared as follows: [***]. A settlement or consent judgment or other voluntary final disposition of a suit under this Section 10.6.5 shall not be entered into without the
consent of the Party not bringing the suit. 

  

	10.7.	 Inventions Owned by Each Party. Notwithstanding anything to the contrary contained in
Section 10.1 (Joint Ownership), the Parties agree that all rights to Collaborator Inventions shall be the exclusive property of Collaborator and all rights [***] shall be the exclusive property of [***]. Each Party shall:
(i) be entitled to file and prosecute in its own name applications for Patents in respect of Inventions it owns; and (ii) own Patents that issue from any such applications. [***]. 

 

	10.8.	 Mutual Freedom to Operate. Each Party hereby grants to the other Party a non-exclusive, worldwide, royalty-free, fully paid-up, transferable and sublicensable license [***].

 

	10.9.	 Termination. [***] provided, however that the license granted in subsection (c) of
Section 10.8 (Mutual Freedom to Operate) shall survive such expiration or termination except that if a Party terminates the Agreement pursuant to Section 6.3 (Termination for Breach), then only the
grant to the terminating Party from the non-terminating Party shall survive. 

  

	10.10.	 Ownership of Other Inventions. Ownership of all Inventions other than Joint Inventions, MSD
Inventions and Collaborator Inventions shall be based on inventorship as determined under United States patent law. 

11.    REPRINTS; REFERENCES IN PUBLICATION. 

Consistent with Applicable Law (including copyright law), each Party may use, refer to, and disseminate reprints of scientific, medical and
other published articles and materials from journals, conferences or symposia relating to the MSD Compound Study that disclose the name of a Party, provided, however, that such use does not constitute an endorsement of any commercial product or
service by the other Party. 

  
 29 

 12.    PUBLICATIONS; PRESS RELEASES. 

 

	12.1.	 Clinical Trial Registry. Collaborator shall register the MSD Compound Study and Collaborator
Clinical Trial with the clinical trials registry located at www.clinicaltrials.gov (or any non-U.S. equivalent clinical trial registry), shall list MSD as a collaborator with respect to the Collaborator
Clinical Trial, and shall timely publish the results following completion of the MSD Compound Study, after taking appropriate action to secure any intellectual property rights arising from the MSD Compound Study. The results of the MSD Compound
Study will be published in accordance with the Protocol. 

  

	12.2.	 Publication. Each Party shall use reasonable efforts to publish or present scientific papers with
respect to the MSD Compound Study in accordance with accepted scientific practice. The Parties agree that, prior to submission of the results of the MSD Compound Study for publication or presentation or any other dissemination of such results
(including oral dissemination), the publishing Party shall invite the other to comment on the content of the material to be published, presented, or otherwise disseminated according to the following procedure: 

 

	 	12.2.1.	 At least [***], the publishing Party shall provide to the other Party the full details of the proposed
publication, presentation, or dissemination in an electronic version as an email attachment. Upon written request from the other Party, the publishing Party agrees not to submit data for publication/presentation/dissemination for an additional [***]
to allow for actions to be taken to preserve rights for patent protection. 

  

	 	12.2.2.	 The publishing Party shall reasonably consider any request by the other Party made within the periods set forth
in Section 12.2.1 to modify the publication and the Parties shall work together to timely resolve any issue regarding the content for publication. Notwithstanding the foregoing, MSD Clinical Data shall be subject to final
review and approval by MSD, not to be unreasonably withheld. 

  

	 	12.2.3.	 The publishing Party shall remove all Confidential Information of the other Party before finalizing the
publication. 

  

	12.3.	 Press Releases. Promptly following the Effective Date, Collaborator may issue the press release
attached hereto as Exhibit E. Unless otherwise required by Applicable Law or rules of a securities exchange upon which a Party’s securities are listed, neither Party shall make any other public announcement concerning this Agreement
without the prior written consent of the other Party. To the extent a Party desires to make such public announcement, such Party shall provide the other Party with a draft thereof at least [***] prior to the date on which such Party would like to
make the public announcement. If a Party believes a disclosure concerning this Agreement is necessary to comply with Applicable Law or rules of a securities exchange, such Party shall promptly inform the other Party of the disclosure that is being
sought, and consult and cooperate fully with the other Party in order to provide the other Party an opportunity to challenge or limit the disclosure obligations. Any information disclosed shall remain otherwise subject to the confidentiality and non-use provisions of this Agreement, and the Party disclosing the information shall take all steps reasonably necessary, including without limitation obtaining an order of confidentiality, to ensure the continued
confidential treatment of such information. 

  
 30 

 13.    REPRESENTATIONS AND WARRANTIES; DISCLAIMERS. 

 

	13.1.	 Due Authorization. Each of Collaborator and MSD represents and warrants to the other that:
(i) it has the corporate power and authority and the legal right to enter into this Agreement and perform its obligations hereunder; (ii) it has taken all necessary corporate action on its part required to authorize the execution and
delivery of this Agreement and the performance of its obligations hereunder; and (iii) this Agreement has been duly executed and delivered on behalf of such Party and constitutes a legal, valid and binding obligation of such Party that is
enforceable against it in accordance with its terms. 

  

	13.2.	 Compounds. 

 

	 	13.2.1.	 Collaborator Compound. Collaborator hereby represents and warrants to MSD that:
(i) Collaborator has the full right, power and authority to grant all of the licenses granted to MSD under this Agreement; (ii) Collaborator Controls the Collaborator Compound; and (iii) at the time of Delivery of the Collaborator
Compound, such Collaborator Compound shall have been Manufactured and supplied in compliance with its Specifications and all Applicable Law. 

  

	 	13.2.2.	 MSD Compound. MSD hereby represents and warrants to Collaborator that: (i) MSD has the full
right, power and authority to grant all of the licenses granted to Collaborator under this Agreement; (ii) MSD Controls the MSD Compound; and (iii) at the time of Delivery of the MSD Compound, such MSD Compound shall have been Manufactured
and supplied in compliance with its Specifications, the Clinical Quality Agreement, and all Applicable Law. 

  

	13.3.	 Results. Neither Party undertakes that the MSD Compound Study shall lead to any particular
result, nor is the success of the MSD Compound Study guaranteed. Neither Party shall be liable for any use that the other Party may make of the Joint Clinical Data or shared Sample Testing Results, nor for advice or information given in connection
therewith. 

  
 31 

	13.4.	 Anti-Corruption. 

 

	 	13.4.1.	 The Parties acknowledge that the corporate policies or Codes of Conduct of Collaborator and MSD and their
respective Affiliates require that each Party’s business be conducted within the letter and spirit of the law. Each Party agrees to conduct the business contemplated herein in a manner that is consistent with all Applicable Law, including the
FCPA. 

  

	 	13.4.2.	 Each Party represents and warrants that it and its Related Entities have not, and covenants that it and its
Related Entities will not, in connection with the performance of this Agreement, directly or indirectly, make, promise, authorize, ratify or offer to make, or take any action in furtherance of, any payment or transfer of anything of value for the
purpose of influencing, inducing or rewarding any act, omission or decision to secure an improper advantage; or improperly assisting it in obtaining or retaining business for it or the other Party, or in any way with the purpose or effect of public
or commercial bribery. 

  

	 	13.4.3.	 Neither Party shall contact, or otherwise knowingly meet with, any Government Official for the purpose of
discussing activities arising out of or in connection with this Agreement without the prior written approval of the other Party, except where such meeting is consistent with the purpose and terms of this Agreement and in compliance with Applicable
Law. 

  

	 	13.4.4.	 Each Party represents and warrants that it: (i) is not excluded, debarred, suspended, proposed for
suspension or debarment, in Violation or otherwise ineligible for government programs; (ii) has not employed or subcontracted with any Person for the performance of the MSD Compound Study who is excluded, debarred, suspended, proposed for
suspension or debarment, or is in Violation or otherwise ineligible for government programs; and (iii) has conducted appropriate anti-corruption and bribery (e.g. FCPA) due-diligence review of all Third
Parties it may hire to act on its behalf in connection with its performance under this Agreement. 

  

	 	13.4.5.	 Each Party represents and warrants that, except as disclosed to the other in writing prior to the Effective
Date, such Party: (i) does not have any interest that directly or indirectly conflicts with its proper and ethical performance of this Agreement; (ii) shall maintain arm’s length relations with all Third Parties with which it deals
for or on behalf of the other in performance of this Agreement; and (iii) has provided complete and accurate information and documentation to the other Party, the other Party’s Affiliates and its and their personnel in the course of any
due diligence conducted by the other Party for this Agreement, including disclosure of any officers, employees, owners or Persons directly or indirectly retained by such Party in relation to the performance of this Agreement who are Government
Officials or relatives of Government Officials. Each Party shall make all further disclosures to the other Party as are necessary to ensure the information provided remains complete and accurate throughout the Term. Subject to the foregoing, each
Party agrees that prior to hiring or retaining any Government Official to assist in its performance of this Agreement it shall obtain the written consent of the other Party and complete a satisfactory anti-corruption and bribery (e.g., FCPA) due
diligence review of such Government Official consistent with industry standards. Each Party further covenants that any future information and documentation submitted to the other Party as part of further due diligence or a certification shall be
complete and accurate. 

  
 32 

	 	13.4.6.	 Each Party shall have the right during the Term, [***], to conduct an investigation and audit of the other
Party’s activities, books and records, to the extent they relate to that other Party’s performance under this Agreement, to verify compliance with the terms of this Section 13.4. Such other Party shall cooperate
fully with such investigation or audit, the scope, method, nature and duration of which shall be at the sole reasonable discretion of the Party requesting such audit. 

 

	 	13.4.7.	 Each Party shall use commercially-reasonable efforts to ensure that all transactions under the Agreement are
properly and accurately recorded in all material respects on its books and records and that each document upon which entries in such books and records are based is complete and accurate in all material respects. Each Party further represents,
warrants and covenants that all books, records, invoices and other documents relating to payments and expenses under this Agreement are and shall be complete and accurate and reflect in reasonable detail the character and amount of transactions and
expenditures. Each Party shall maintain a system of internal accounting controls reasonably designed to ensure that no off-the-books or similar funds or accounts will be
maintained or used in connection with this Agreement. 

  

	 	13.4.8.	 Each Party agrees that in the event that the other Party believes in good faith that there has been a possible
violation of any provision of this Section 13.4, such other Party may make full disclosure of such belief and related information (including, if necessary, Confidential Information) needed to support such belief at any time
and for any reason to any competent government bodies and agencies, and to anyone else such Party determines in good faith has a legitimate need to know. 

  

	 	13.4.9.	 Each Party shall comply with its own ethical business practices policy and any corporate integrity agreement
(if applicable) to which it is subject. Each Party shall ensure that all of its employees involved in performing its obligations under this Agreement are made specifically aware of the compliance requirements under this
Section 13.4. In addition, each Party shall ensure that all such employees participate in and complete mandatory compliance training to be conducted by each Party, including specific training on anti-bribery and corruption,
prior to their performance of any obligations or activities under this Agreement. Each Party shall certify its continuing compliance with the requirements under this Section 13.4 on a periodic basis during the Term in such
form as may be reasonably specified by the other Party. 

  
 33 

	 	13.4.10.	 Each Party shall have the right to terminate this Agreement immediately in accordance with
Section 6.3 (Termination for Breach) in the event of any violation of this Section 13.4 by the other Party. 

 

	13.5.	 DISCLAIMER. EXCEPT AS EXPRESSLY PROVIDED HEREIN, MSD MAKES NO WARRANTIES,
EXPRESS OR IMPLIED WITH RESPECT TO THE MSD COMPOUND, AND COLLABORATOR MAKES NO WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE COLLABORATOR COMPOUND, IN EACH CASE INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

 14.    INSURANCE; INDEMNIFICATION; LIMITATION OF LIABILITY. 

 

	14.1.	 Insurance. Each Party warrants that it maintains a policy or program of insurance or
self-insurance at levels sufficient to support the indemnification obligations assumed herein. Upon request, a Party shall provide evidence of such insurance. 

 

	14.2.	 Indemnification. 

 

	 	14.2.1.	 Indemnification by Collaborator. Collaborator agrees to defend, indemnify and hold harmless MSD,
its Affiliates, and its and their employees, officers, directors, Subcontractors and agents from and against any Liability, except to the extent that such Liability [***]. 

 

	 	14.2.2.	 Indemnification by MSD. MSD agrees to defend, indemnify and hold harmless Collaborator, its
Affiliates, and its and their employees, officers, directors, Subcontractors and agents from and against any Liability to the extent such Liability was directly caused by: [***]. 

 

	 	14.2.3.	 Procedure. The obligations of MSD and Collaborator under this Section 14.2
(Indemnification) are conditioned upon the delivery of written notice to the indemnifying Party of any potential Liability within a reasonable time after the indemnified Party becomes aware of such potential Liability. The indemnifying Party
will have the right to assume the defense of any suit or claim related to the Liability (using counsel reasonably satisfactory to the indemnified Party) if it has assumed responsibility for the suit or claim in writing; provided that the indemnified
Party may assume the responsibility for such defense to the extent the indemnifying Party does not do so in a timely manner). The indemnified Party may participate in (but not control) the defense thereof at its sole cost and expense. The Defending
Party shall keep the Other Party advised of the status of such action, suit, proceeding or claim and the defense thereof and shall consider recommendations made by the Other Party with respect thereto. The Defending Party shall not agree to any
settlement of such action, suit, proceeding or claim without the prior written consent of the Other Party, which shall not be unreasonably withheld, conditioned or delayed. The Defending Party, but solely to the extent the Defending Party is also
the indemnifying Party, shall not agree to any settlement of such action, suit, proceeding or claim or consent to any judgment in respect thereof that does not include a complete and unconditional release of the Other Party from all liability with
respect thereto or that imposes any liability or obligation on the Other Party without the prior written consent of the Other Party. 

  
 34 

	 	14.2.4.	 MSD Compound Study Subjects. Neither Party shall offer compensation on behalf of the other Party
to any MSD Compound Study subject or bind the other Party to any indemnification obligations in favor of any MSD Compound Study subject. 

  

	14.3.	 LIMITATION OF LIABILITY. IN NO EVENT SHALL EITHER PARTY, ITS AFFILIATES AND ITS
OR THEIR EMPLOYEES, DIRECTORS, SUBCONTRACTORS OR AGENTS BE LIABLE TO THE OTHER PARTY UNDER ANY THEORY FOR, NOR SHALL ANY INDEMNIFIED PARTY HAVE THE RIGHT TO RECOVER, ANY SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR OTHER SIMILAR DAMAGES, ANY
PUNITIVE DAMAGES, ANY LOST PROFIT, LOST SALE OR LOST OPPORTUNITY DAMAGES (WHETHER SUCH CLAIMED DAMAGES ARE DIRECT OR INDIRECT), ARISING DIRECTLY OR INDIRECTLY OUT OF OR RELATED TO THIS AGREEMENT, THE ACTIVITIES TO BE CONDUCTED BY THE PARTIES
HEREUNDER OR THE COLLABORATOR CLINICAL TRIAL (INCLUDING THE MSD COMPOUND STUDY). SUCH LIMITATION SHALL NOT APPLY TO DAMAGES PAID OR PAYABLE TO A THIRD PARTY BY AN INDEMNIFIED PARTY FOR WHICH IT IS ENTITLED TO INDEMNIFICATION HEREUNDER OR WITH
RESPECT TO DAMAGES ARISING OUT OF OR RELATED TO A PARTY’S BREACH OF ITS OBLIGATIONS UNDER THIS AGREEMENT WITH RESPECT TO[***]. 

15.    USE OF NAME. 

Except as otherwise provided herein or required under Applicable Law, neither Party shall have any right, express or implied, to use in any
manner the name or other designation of the other Party or any other trade name, trademark or logo of the other Party for any purpose in connection with the performance of this Agreement without the other Party’s prior written consent. 

  
 35 

 16.    FORCE MAJEURE. 

If, in the performance of this Agreement, one of the Parties is prevented, hindered or delayed by reason of any cause beyond such Party’s
reasonable control (e.g., war, riots, fire, strike, acts of terror, governmental action and governmental laws), such Party shall be excused from performance to the extent that it is necessarily prevented, hindered or delayed. The non-performing Party shall notify the other Party of any such event within [***] after such occurrence by giving notice to the other Party stating the nature of the event, its anticipated duration, and any action
being taken to avoid or minimize its effect. The suspension of performance will be of no greater scope and no longer duration than is necessary and the non-performing Party shall use commercially reasonable
efforts to remedy its inability to perform. 
 17.    ENTIRE AGREEMENT; AMENDMENT; WAIVER. 

This Agreement, together with the Appendices, Exhibits and Schedules hereto and the Related Agreements, constitutes the sole, full and complete
agreement by and between the Parties with respect to the subject matter of this Agreement, and all prior agreements, understandings, promises and representations, whether written or oral, with respect thereto are superseded by this Agreement. In the
event of a conflict between a Related Agreement and this Agreement, the terms of this Agreement shall control except: (i) in the event of any inconsistencies between the terms of this Agreement and the Data Protection Terms, [***]; (ii) in
the event of any inconsistency between the terms of this Agreement and the Pharmacovigilance Agreement [***]. No amendments, changes, additions, deletions or modifications to or of this Agreement shall be valid unless reduced to writing and signed
by the Parties hereto. Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on
behalf of the Party waiving such term or condition. The waiver by either Party of any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or
failure by said other Party whether of a similar nature or otherwise. 
 18.    ASSIGNMENT AND AFFILIATES. 

Neither Party shall assign or transfer this Agreement without the prior written consent of the other Party; provided, however, that either
Party may assign all or any part of this Agreement without the other Party’s consent: (i) to one or more of its Affiliates, and any and all rights and obligations of either Party may be exercised or performed by its Affiliates, provided in
each case, that such Affiliates agree to be bound by this Agreement; or (ii) in connection with the sale of all or substantially all of its assets to which this Agreement relates, whether by merger, acquisition or similar transaction or series
of related transactions. This Agreement shall be binding upon the successors and permitted assigns of the Parties and the name of a Party appearing herein shall be deemed to include the names of such Party’s successors and permitted assigns to
the extent necessary to carry out the intent of the Agreement. Any assignment not in accordance with this Article 18 shall be null, void and of no legal effect. 

  
 36 

 19.    CHANGE OF CONTROL. 

If Collaborator undergoes a Change of Control in which the acquiring party owns or controls a competing
PD-1 Antagonist, then upon MSD’s request, the Parties and the acquiring party shall engage in discussion and shall adopt reasonable procedures to be agreed with MSD to prevent the disclosure of Sensitive
Information beyond Collaborator’s personnel having access to or knowledge of Sensitive Information prior to the Change of Control and other personnel of the acquiring party approved by MSD, and to control the dissemination of Sensitive
Information disclosed after the Change of Control to prevent the use of Sensitive Information for the development or commercialization of competing PD-1 Antagonist products. Such procedures shall include
provisions allowing designated management personnel to review and evaluate on a comparative basis business and technical plans and information regarding the Combination, the MSD Compound, and competing PD-1
Antagonist Products, in connection with portfolio decision-making (but not, for clarity, for use in development or commercialization of competing PD-1 Antagonist products). 

20.    INVALID PROVISION. 

If any provision of this Agreement is held to be illegal, invalid or unenforceable, the remaining provisions shall remain in full force and
effect and will not be affected by the illegal, invalid or unenforceable provision. In lieu of the illegal, invalid or unenforceable provision, the Parties shall negotiate to agree upon a reasonable provision that is legal, valid and enforceable to
carry out as nearly as practicable the original intention of the entire Agreement. 
 21.    GOVERNING LAW; DISPUTE RESOLUTION.

  

	21.1.	 The Parties shall attempt to settle all disputes arising out of or in connection with this Agreement in an
amicable manner. Any claim, dispute or controversy arising out of or relating to this Agreement, including the breach, termination or validity hereof or thereof, shall be governed by and construed in accordance with the substantive laws of the State
of New York, without giving effect to its choice of law principles. 

  
 37 

	21.2.	 Nothing contained in this Agreement shall deny either Party the right to seek injunctive or other equitable
relief from a court of competent jurisdiction in the context of a bona fide emergency or prospective irreparable harm, and such an action may be filed or maintained notwithstanding any ongoing discussions between the Parties. 

22.    NOTICES. 
 All
notices or other communications that are required or permitted hereunder shall be in writing and delivered personally, sent by facsimile or email (and promptly confirmed by personal delivery or overnight courier), or sent by
internationally-recognized overnight courier addressed as follows: 
 If to Collaborator, to the address(es) set forth in the
Collaborator Notice Block on the Information Sheet. 
 If to MSD, to: 

MSD International GmbH 
 [***]

 MSD International Business GmbH 

[***] 
 With copies (which shall
not constitute notice) to: 
 [***] 

23.    RELATIONSHIP OF THE PARTIES. 

The relationship between the Parties is and shall be that of independent contractors, and does not and shall not constitute a partnership,
joint venture, agency or fiduciary relationship. Neither Party shall have the authority to make any statements, representations or commitments of any kind, or bind the other Party, except with the other Party’s express prior written consent.
All Persons employed by a Party will be the employees of such Party and not of the other Party and all costs and obligations incurred by reason of any such employment shall be for the account and expense of such Party. 

  
 38 

 24.    COUNTERPARTS AND DUE EXECUTION. 

This Agreement and any amendment may be executed in any number of counterparts (including by electronic transmission), each of which shall be
deemed an original, but all of which together constitute one and the same instrument, notwithstanding any electronic transmission, storage or printing of this Agreement. When executed by the Parties, this Agreement shall constitute an original
instrument, notwithstanding any electronic transmission, storage or printing of this Agreement. For clarity, signatures transmitted by PDF shall be treated as original signatures. 

25.    CONSTRUCTION. 

Except where the context otherwise requires, wherever used, the singular includes the plural and vice versa, the use of any gender will be
applicable to all genders, and the word “or” is used in the inclusive sense (and/or). Whenever this Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days. The captions of this
Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The term “including” as used herein
shall be deemed to be followed by the phrase “without limitation” or like expression. The term “will” as used herein means shall. The terms “hereof”, “hereto”,
“herein” and “hereunder” and words of similar import when used in this Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement. References to “Article,”
“Section”, “Exhibit” or “Schedule” are references to the numbered sections of this Agreement and the appendices attached to this Agreement, unless expressly stated otherwise. A reference to any
statute, law, rule, regulation or directive will be construed as a reference to such statute, law, rule, regulation or directive as amended, extended, repealed and replaced or re-enacted from time to time. A
definition of or reference to any agreement, instrument or document herein shall refer to such agreement, instrument or other document as it may be amended, supplemented or otherwise modified from time to time (subject to any restrictions on such
amendments, supplements or modifications set forth herein). Any reference to “agree,” “consent,” “approve” or the like shall require that such agreement, consent or approval be specific and in writing, whether by
written agreement, letter, approved minutes or otherwise (but excluding e-mail and instant messaging). Except where the context otherwise requires, references to this “Agreement” shall include
the appendices and schedules attached to this Agreement. The language of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction will be applied against either Party hereto. 

[Remainder of page intentionally left blank. Signature page follows.] 

  
 39 

 IN WITNESS WHEREOF, the respective representatives of the Parties have executed this
Agreement as of the Effective Date. 
 IO Biotech ApS 
  

			
	By:	 	 /s/ Mai-Britt Zocca

	
	 Mai-Britt Zocca, Ph.D.

	Name
	
	 Chief Executive Officer; Director

	Title	 	

 MSD International GmbH 
  

			
	By:	 	 /s/ Franz Escherich

	
	 Franz Escherich

	Name
	
	 Director

	Title	 	

 MSD International Business GmbH 
  

			
	By:	 	 /s/ Carlos Fernandez

	
	 Carlos Fernandez

	Name
	
	 Director

	TitleExhibit 10.1

 

THIS PROMISSORY NOTE (“NOTE”) HAS NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT
BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL
REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

 

PROMISSORY NOTE

	 	 	 
	Principal Amount: $1,500,000	 	Dated as of November 30, 2021

 

Crown PropTech Acquisitions., a Cayman Islands exempted company and
blank check company (the “Maker”), promises to pay to the order of Richard Chera, or its registered assigns or successors
in interest (the “Payee”), or order, the principal sum of ONE MILLION FIVE HUNDRED THOUSAND U.S. dollars ($1,500,000)
in lawful money of the United States of America, on the terms and conditions described below. All payments on this Note shall be made
by check or wire transfer of immediately available funds or as otherwise determined by the Maker to such account as the Payee may from
time to time designate by written notice in accordance with the provisions of this Note.

 

1. Principal. The principal balance of this Note shall be payable
on the earlier of: (i) twelve (12) months from the date hereof or (ii) the date on which Maker consummates a business combination (the
 “Due Date”); provided, however, that the Maker may prepay the principal balance at any time prior to the Due Date.

 

2. Interest. No interest shall accrue on the unpaid principal
balance of this Note.

 

3. Application of Payments. All payments shall be applied first
to payment in full of any costs incurred in the collection of any sum due under this Note, including (without limitation) reasonable attorney’s
fees, then to the payment in full of any late charges and finally to the reduction of the unpaid principal balance of this Note.

 

4. Conversion.

 

(a) Notwithstanding anything contained in this
Note to the contrary, at Payee’s option, at any time prior to payment in full of the principal balance of this Note, Payee may elect
to convert all or any portion of the unpaid principal balance of this Note into that number of warrants consisting of one warrant exercisable
for one ordinary share of the Maker (the “Convertible Warrants”), equal to: (x) the portion of the principal amount
of this Note being converted pursuant to this Section 4, divided by (y) $1.50, rounded up to the nearest whole number of warrants. The
Convertible Warrants shall be identical to the warrants issued by the Maker to Crown PropTech Sponsor, LLC in the private placement that
occurred upon consummation of the Maker’s initial public offering. The Convertible Warrants and their underlying securities, and
any other equity security of Maker issued or issuable with respect to the foregoing by way of a share dividend or share split or in connection
with a combination of shares, recapitalization, amalgamation, consolidation or reorganization, shall be entitled to the registration rights
set forth in Section 5 hereof.

 

(b) Upon any complete or partial conversion of
the principal amount of this Note, (i) such principal amount shall be so converted and such converted portion of this Note shall become
fully paid and satisfied, (ii) Payee shall surrender and deliver this Note, duly endorsed, to Maker or such other address which Maker
shall designate against delivery of the Convertible Warrants, (iii) Maker shall promptly deliver a new duly executed Note to Payee in
the principal amount that remains outstanding, if any, after any such conversion and (iv) in exchange for all or any portion of the surrendered
Note, Maker shall, at the direction of Payee, deliver to Payee (or its members or their respective affiliates) (Payee or such other persons,
the “Holders”) the Convertible Warrants, which shall bear such legends as are required, in the opinion of counsel to
Maker or by any other agreement between Maker and Payee and applicable state and federal securities laws.

 

(c) The Holders shall pay any and all issue and
other taxes that may be payable with respect to any issue or delivery of the Convertible Warrants upon conversion of this Note pursuant
hereto; provided, however, that the Holders shall not be obligated to pay any transfer taxes resulting from any transfer requested by
the Holders in connection with any such conversion.

 

(d) The Convertible Warrants shall not be issued
upon conversion of this Note unless such issuance and such conversion comply with all applicable provisions of law.

 

     

     

    

  

5. Registration Rights.

 

(a) Reference is made to that certain Registration Rights Agreement
between Brivo, Inc. and the parties thereto, dated as of November 10, 2021, 2021 (the “Registration Rights Agreement”). All
capitalized terms used in this Section 5 shall have the same meanings ascribed to them in the Registration Rights Agreement.

 

(b) For the avoidance of doubt, the underlying securities to the Convertible
Warrants held by the Payee shall constitute Registrable Securities under the Registration Rights Agreement.

 

6. Events of Default. The following shall constitute an event
of default (“Event of Default”):

 

(a) Failure to Make Required Payments. Failure by Maker to pay
the principal amount due pursuant to this Note within five (5) business days of the date specified above.

 

(b) Voluntary Bankruptcy, Etc. The commencement by Maker of
a voluntary case under any applicable bankruptcy, insolvency, reorganization, rehabilitation or other similar law, or the consent by it
to the appointment of or taking possession by a receiver, liquidator, assignee, trustee, custodian, sequestrator (or other similar official)
of Maker or for any substantial part of its property, or the making by it of any assignment for the benefit of creditors, or the failure
of Maker generally to pay its debts as such debts become due, or the taking of corporate action by Maker in furtherance of any of the
foregoing.

 

(c) Involuntary Bankruptcy, Etc. The entry of a decree or order
for relief by a court having jurisdiction in the premises in respect of Maker in an involuntary case under any applicable bankruptcy,
insolvency or other similar law, or appointing a receiver, liquidator, assignee, custodian, trustee, sequestrator (or similar official)
of Maker or for any substantial part of its property, or ordering the winding-up or liquidation of its affairs, and the continuance of
any such decree or order unstayed and in effect for a period of sixty (60) consecutive days.

 

7. Remedies.

 

(a) Upon the occurrence of an Event of Default specified in Section
6(a) hereof, Payee may, by written notice to Maker, declare this Note to be due immediately and payable, whereupon the unpaid principal
amount of this Note, and all other amounts payable thereunder, shall become immediately due and payable without presentment, demand, protest
or other notice of any kind, all of which are hereby expressly waived, anything contained herein or in the documents evidencing the same
to the contrary notwithstanding.

 

(b) Upon the occurrence of an Event of Default specified in Sections
6(b) and 6(c), the unpaid principal balance of this Note, and all other sums payable with regard to this Note, shall automatically and
immediately become due and payable, in all cases without any action on the part of Payee.

 

8. Waivers. Maker and all endorsers and guarantors of, and sureties
for, this Note waive presentment for payment, demand, notice of dishonor, protest, and notice of protest with regard to the Note, all
errors, defects and imperfections in any proceedings instituted by Payee under the terms of this Note, and all benefits that might accrue
to Maker by virtue of any present or future laws exempting any property, real or personal, or any part of the proceeds arising from any
sale of any such property, from attachment, levy or sale under execution, or providing for any stay of execution, exemption from civil
process, or extension of time for payment; and Maker agrees that any real estate that may be levied upon pursuant to a judgment obtained
by virtue hereof, on any writ of execution issued hereon, may be sold upon any such writ in whole or in part in any order desired by Payee.

 

9. Unconditional Liability. Maker hereby waives all notices
in connection with the delivery, acceptance, performance, default, or enforcement of the payment of this Note, and agrees that its liability
shall be unconditional, without regard to the liability of any other party, and shall not be affected in any manner by any indulgence,
extension of time, renewal, waiver or modification granted or consented to by Payee, and consents to any and all extensions of time, renewals,
waivers, or modifications that may be granted by Payee with respect to the payment or other provisions of this Note, and agrees that additional
makers, endorsers, guarantors, or sureties may become parties hereto without notice to Maker or affecting Maker’s liability hereunder.

 

10. Notices. All notices, statements or other documents which
are required or contemplated by this Note shall be: (i) in writing and delivered personally or sent by first class registered or certified
mail, overnight courier service or facsimile or electronic transmission to the address designated in writing, (ii) by facsimile to the
number most recently provided to such party or such other address or fax number as may be designated in writing by such party or (iii)
by electronic mail, to the electronic mail address most recently provided to such party or such other electronic mail address as may be
designated in writing by such party. Any notice or other communication so transmitted shall be deemed to have been given on the day of
delivery, if delivered personally, on the business day following receipt of written confirmation, if sent by facsimile or electronic transmission,
one (1) business day after delivery to an overnight courier service or five (5) days after mailing if sent by mail.

 

     

     

    

 

11. Construction. THIS NOTE SHALL BE CONSTRUED AND ENFORCED
IN ACCORDANCE WITH THE LAWS OF NEW YORK, WITHOUT REGARD TO CONFLICT OF LAW PROVISIONS THEREOF.

 

12. Severability. Any provision contained in this Note which
is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or
unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction
shall not invalidate or render unenforceable such provision in any other jurisdiction.

 

13. Trust Waiver. Notwithstanding anything herein to the contrary,
the Payee hereby waives any and all right, title, interest or claim of any kind (“Claim”) in or to any distribution
of or from the trust account in which the proceeds of the initial public offering (the “IPO”) conducted by the Maker
(including the deferred underwriting discounts and commissions) and the proceeds of the sale of the warrants issued in a private placement
that occurred in connection with the IPO were deposited, as described in greater detail in the registration statement and prospectus filed
with the Securities and Exchange Commission in connection with the IPO, and hereby agrees not to seek recourse, reimbursement, payment
or satisfaction for any Claim against the trust account for any reason whatsoever.

 

14. Amendment; Waiver. Any amendment hereto or waiver of any
provision hereof may be made with, and only with, the written consent of the Maker and the Payee.

 

15. Assignment. No assignment or transfer of this Note or any
rights or obligations hereunder may be made by any party hereto (by operation of law or otherwise) without the prior written consent of
the other party hereto and any attempted assignment without the required consent shall be void.

 

[Signature page follows]

 

     

     

    

 

IN WITNESS WHEREOF, Maker, intending to be legally bound hereby,
has caused this Note to be duly executed by the undersigned as of the day and year first above written.

 

	 	 	 	 
	 	CROWN PROPTECH ACQUISITION
	 	
    a Cayman Islands exempted company

	 	 	 
	 	 	 
	 	By:	
    /s/ Pius Sprenger

	 	 	Name:	Pius Sprenger
	 	 	Title:	
    Chief Financial Officer

 

 

 

	 	RICHARD CHERA 
	 	 
	 	 	 
	 	By:	
    /s/ Richard Chera

	 	 	Name:	Richard Chera
	 	 	 	 

 

 

 

 

 

[Signature Page to Promissory Note]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}]]